2009
DOI: 10.1118/1.3182496
|View full text |Cite
|
Sign up to set email alerts
|

WE-C-304A-09: QA Procedures for Multi-Modality Preclinical Tumor Drug Response Testing

Abstract: Purpose: There are growing expectations that imaging biomarkers can speed preclinical testing of anti‐tumor drugs in rodent models. The only presently accepted imaging biomarker by the US Food and Drug Administration (FDA) is tumor size measurement based on WHO or RECIST criteria. Standardized Tumor Response QA procedures are needed to allow accurate tumor size measurements in rodent models coming from multiple devices and laboratories. This project tests the hypothesis that development and testing of new anti… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles